Managers / Q3 2020 · view latest →
SV Health Investors, LLC
CIK 0001587143 · ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON, MA, 02108 · 617-367-8100
Summary
Sv Health Investors, LLC reported $197M in U.S.-listed holdings across 10 positions for Q3 2020.
The portfolio is heavily concentrated: American Well alone accounts for 29.3% of reported value.
Compared with Q2 2020, the fund opened 1 new position and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 46.7% · $92M
- Common Stock · 34.8% · $69M
- ADR · 18.5% · $36M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AMERICAN WELL CORP | NEW | +1.95M | 1.95M | +$58M | $58M |
| OCULOCULAR THERAPEUTIX INC | SOLD OUT | −312.1K | 0 | −$3M | $0 |
| BCYCBICYCLE THERAPEUTICS PLC | HELD | +0 | 1.92M | +$6M | $36M |
| AVROBIO INC | HELD | +0 | 1.24M | −$5M | $16M |
| SUTRO BIOPHARMA INC | HELD | +0 | 1.82M | +$4M | $18M |
| DECIPHERA PHARMACEUTICALS INC | HELD | +0 | 450.0K | −$4M | $23M |
| MISONIX, INC. | HELD | +0 | 1.70M | −$3M | $20M |
| KALVISTA PHARMACEUTICALS INC | HELD | +0 | 1.72M | +$844,000 | $22M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | AMERICAN WELL CORP | COM NEW | 29.27% | $58M | 1.95M |
| 2 | BCYCBICYCLE THERAPEUTICS PLChistory → | SPONSORED ADS | 18.49% | $36M | 1.92M |
| 3 | DECIPHERA PHARMACEUTICALS INC | COM | 11.69% | $23M | 450.0K |
| 4 | KALVISTA PHARMACEUTICALS INC | COM | 10.97% | $22M | 1.72M |
| 5 | MISONIX, INC. | COM | 10.08% | $20M | 1.70M |
| 6 | SUTRO BIOPHARMA INC | COM | 9.29% | $18M | 1.82M |
| 7 | AVROBIO INC | COM | 8.15% | $16M | 1.24M |
| 8 | X4 PHARMACEUTICALS INC | COM | 1.07% | $2M | 311.5K |
| 9 | CATABASIS PHARMACEUTICALS IN | COM NEW | 0.90% | $2M | 285.8K |
| 10 | TRANSENTERIX INC | COM NEW | 0.09% | $177,000 | 510.1K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2022 | $32M | 4 | Nov 7, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $44M | 5 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $83M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $155M | 6 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $204M | 8 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $230M | 7 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $267M | 8 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $208M | 9 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $197M | 10 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $144M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $119M | 10 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $165M | 10 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 10 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $149M | 9 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $170M | 8 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $162M | 9 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 2 additional managers.
- SVLSF VI, LLC028-19256
- SV Life Sciences Fund VI (GP), L.P.028-19255
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.